

Haematologica
HAEMATOL/2019/243410
Version 4

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Ali Bazarbachi, Gesine Bug, Frederic Baron, Eolia Brissot, Fabio Ciceri, Iman Abou Dalle, Hartmut Döhner, Jordi Esteve, Yngvar Floisand, Sebastian Giebel, Maria Gilleece, Norbert-Claude Gorin, Elias Jabbour, Mahmoud Aljurf, Hagop Kantarjian, Mohamed Kharfan Dabaja, Myriam Labopin, Francesco Lanza, Florent Malard, Zinaida Peric, Thomas Prebet, Farhad Ravandi, Annalisa Ruggeri, Jaimie Sanz, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Norbert Vey, Bipin N. Savani, Arnon Nagler, and Mohamad Mohty

Disclosures: Ali Bazarbachi received honorarium from Novartis and Sanofi and research support from Novartis and Astellas. Gesine Bug received honoraria and travel grants from Novartis, Jazz, Celgene, Pfizer, Gilead, Sanofi, Neovii, Eurocept and Hexal and research funding from Novartis. Elias Jabbour received research grants from Amgen, AbbVie, Adaptive biotechnologies, Takeda, Pfizer, BMS, Spectrum, and Novartis and consultancy and advisory roles from Amgen, AbbVie, Adaptive biotechnologies, Takeda, Pfizer, BMS, Spectrum, Daiichi Sanko, and Astellas. Mohamed A. Kharfan Dabaja received advisory role for Daiichi Sankyo. Mohamad Mohty received Honoraria from Novartis and Daiichi Sankyo. Farhad Ravandi received Honoraria and advisory board roles from Astellas and Daiichi Sankyo. All remaining authors do not have any conflicts of interest. No financial support was provided for this work.

Contributions: Two chairpersons (AB and MM) appointed a panel of 32 physicians (hereafter referred to as the Panel) selected mostly from the European Society for Blood and Marrow Transplantation (EBMT) for their expertise in research and clinical practice in AML and allogeneic SCT. A physician with expertise in clinical epidemiology (ML) assured the methodological correctness of the process. Three panelists (AB, MM and ML) drafted statements that addressed the identified key questions, and remaining panelists scored their agreement with those statements and provided suggestions for rephrasing.